Patents Assigned to ElexoPharm GmbH
  • Inhibitors of 17Beta-hydroxysteroid dehydrogenases type 1 and type 2
    Patent number: 9884839
    Abstract: Provided herein are non-steroidal 17beta-hydroxysteroid dehydrogenase type 1 and type 2 (17?-HSD1 and 17?-HSD2) inhibitors, their production and use, especially for the treatment and for prophylaxis of hormone-related diseases.
    Type: Grant
    Filed: January 5, 2015
    Date of Patent: February 6, 2018
    Assignee: ElexoPharm GmbH
    Inventors: Rolf Hartmann, Martin Frotscher, Ahmed Saad Abdelsamie Ahmed, Emmanuel Bey, Chris J. van Koppen, Sandrine Oberwinkler-Marchais, Carsten Börger, Lorenz Siebenbürger, Victor Hernández Olmos
  • Indoline compounds as aldosterone synthase inhibitors
    Patent number: 9745282
    Abstract: This invention relates to indoline compounds of the structural formula: or their pharmaceutically acceptable salts, wherein the variables are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: August 29, 2017
    Assignees: Merck Sharp & Dohme Corp, ElexoPharm GmbH
    Inventors: Amjad Ali, Michael Man-Chu Lo, Edward Metzger, Lina Yin, Rolf Hartmann, Qingzhong Hu, Ralf Heim, Christina Zimmer
  • Indoline compounds as aldosterone synthase inhibitors
    Patent number: 9550750
    Abstract: This invention relates to indo line compounds of the structural formula I, or their pharmaceutically acceptable salts, wherein the variables are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: January 24, 2017
    Assignees: Merck Sharp & Dohme Corp., Elexopharm GMBH
    Inventors: Amjad Ali, Michael Man-Chu Lo, Edward Metzger, Lina Yin, Rolf Hartmann, Qingzhong Hu, Ralf Heim, Christina Zimmer
  • Aldosterone synthase inhibitors
    Patent number: 9278093
    Abstract: This invention relates to tricyclic triazole compounds or their pharmaceutically acceptable salts. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the above-cited compounds or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: March 8, 2016
    Assignees: Merck Sharp & Dohme Corp., ElexoPharm GmbH
    Inventors: Amjad Ali, Emmanuel Bey, Rolf Hartmann, Quingzhong Hu, Lina Yin
  • INDOLINE COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS
    Publication number: 20150225365
    Abstract: This invention relates to indo line compounds of the structural formula I, or their pharmaceutically acceptable salts, wherein the variables are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.
    Type: Application
    Filed: October 2, 2013
    Publication date: August 13, 2015
    Applicants: ElexoPharm GmbH, Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Michael Man-Chu Lo, Edward Metzger, Lina Yin, Rolf Hartmann, Qingzhong Hu, Ralf Heim, Christina Zimmer
  • Aldosterone synthase inhibitors
    Patent number: 9073929
    Abstract: This invention relates to tricyclic triazole analogs of the formula I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: July 7, 2015
    Assignees: ElexoPharm GmbH, Merck Sharp & Dohme Corp.
    Inventors: Scott B. Hoyt, Whitney Lane Petrilli, Clare London, Yusheng Xiong, Jerry Andrew Taylor, Amjad Ali, Michael Man-Chu Lo, Timothy J. Henderson, Qingzhong Hu, Rolf Hartmann, Lina Yin, Ralf Heim, Emmanuel Bey, Rohit Saxena, Swapan Kumar Samanta, Bheemashankar A. Kulkarni
  • 6-pyridin-3-yl-3,4-dihydro-1h-quinolin-2-one derivatives and related compounds as inhibitors of the human aldosterone synthase CYP11B2
    Patent number: 8685960
    Abstract: The invention provides compounds of the general formula (I) which are inhibitors of the human aldosterone synthase, and also pharmaceutical compositions containing these compounds, and the use of these compounds and other heteroaryl substituted quinolinone derivatives for the treatment of hyperaldosteronism and/or disorders or diseases that are mediated by 11 ?-hydroxylase (CYP11 B1).
    Type: Grant
    Filed: May 5, 2009
    Date of Patent: April 1, 2014
    Assignee: Elexopharm GmbH
    Inventors: Rolf W. Hartmann, Ralf Heim, Simon Lucas
  • ALDOSTERONE SYNTHASE INHIBITORS
    Publication number: 20140045819
    Abstract: This invention relates to tricyclic triazole analogues of the formula I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase.
    Type: Application
    Filed: April 20, 2012
    Publication date: February 13, 2014
    Applicants: ElexoPharm GmbH, SCHERING CORPORATION
    Inventors: Scott B. Hoyt, Whitney Lane Petrilli, Clare London, Yusheng Xiong, Jerry Andrew Taylor, Amjad Ali, Michael Man-Chu Lo, Timothy J. Henderson, Qingzhong Hu, Rolf Hartmann, Lina Yin, Ralf Heim, Emmanuel Bey, Rohit Saxena, Swapan Kumar Samanta, Bheemashankar A. Kulkarni
  • Inhibitors of the human aldosterone synthase CYP11B2
    Patent number: 8541404
    Abstract: The invention provides compounds of the general formula (I) which are inhibitors of the human aldosterone synthase, and also pharmaceutical compositions containing these compounds, and a method of treating of hyperaldosteronism and/or disorders or diseases that are mediated by 11?-hydroxylase (CYP11B1) with these compounds.
    Type: Grant
    Filed: November 3, 2010
    Date of Patent: September 24, 2013
    Assignee: ElexoPharm GmbH
    Inventors: Rolf W. Hartmann, Ralf Heim, Simon Lucas